Literature DB >> 11091537

Prognostic and Predictive Factors for Breast Cancer.

.   

Abstract

Prognostic factors can be useful for making decisions about which patients should receive adjuvant therapy, and predictive factors can be used to predict response or lack of response to a particular therapy. We review the standard factors that are available today for primary breast cancer, and we dscribe some of the new, potential prognostic and predictive factors that are currently under investigation.

Entities:  

Year:  1995        PMID： 11091537     DOI： 10.1007/BF02966945

Source DB:  PubMed          Journal:  Breast Cancer        ISSN： 1340-6868            Impact factor:   4.239


  38 in total

1.  Predicting response to endocrine therapy in human breast cancer: a hypothesis.

Authors:  K B Horwitz; W L McGuire
Journal:  Science       Date:  1975-08-29       Impact factor: 47.728

2.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.

Authors:  P R Rosen; S Groshen; P E Saigo; D W Kinne; S Hellman
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

3.  Factors influencing short and long term survival of breast cancer patients.

Authors:  J W Berg; G F Robbins
Journal:  Surg Gynecol Obstet       Date:  1966-06

4.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Authors:  B A Gusterson; R D Gelber; A Goldhirsch; K N Price; J Säve-Söderborgh; R Anbazhagan; J Styles; C M Rudenstam; R Golouh; R Reed
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

5.  Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.

Authors:  Y Remvikos; P Beuzeboc; A Zajdela; N Voillemot; H Magdelénat; P Pouillart
Journal:  J Natl Cancer Inst       Date:  1989-09-20       Impact factor: 13.506

6.  Comparison of an immunocytochemical assay for progesterone receptor with a biochemical method of measurement and immunocytochemical examination of the relationship between progesterone and estrogen receptors.

Authors:  U Berger; P Wilson; S Thethi; R A McClelland; G L Greene; R C Coombes
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

7.  Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods.

Authors:  L B Kinsel; E Szabo; G L Greene; J Konrath; G S Leight; K S McCarty
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

8.  Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.

Authors:  B Têtu; J Brisson
Journal:  Cancer       Date:  1994-05-01       Impact factor: 6.860

9.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

10.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

Authors:  C Wright; S Nicholson; B Angus; J R Sainsbury; J Farndon; J Cairns; A L Harris; C H Horne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640
View more
  10 in total

Review 1.  Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.

Authors:  Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

2.  Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials.

Authors:  Chaeryon Kang; Holly Janes; Parvin Tajik; Henk Groen; Ben Mol; Corine Koopmans; Kim Broekhuijsen; Eva Zwertbroek; Maria van Pampus; Maureen Franssen
Journal:  Stat Med       Date:  2018-02-14       Impact factor: 2.373

3.  Gene expression signature in organized and growth-arrested mammary acini predicts good outcome in breast cancer.

Authors:  Marcia V Fournier; Katherine J Martin; Paraic A Kenny; Kris Xhaja; Irene Bosch; Paul Yaswen; Mina J Bissell
Journal:  Cancer Res       Date:  2006-07-15       Impact factor: 12.701

4.  Prediction of axillary lymph node metastasis in triple-negative breast cancer by multi-omics analysis and an integrated model.

Authors:  Si-Yuan Li; Yu-Wei Li; Ding Ma; Zhi-Ming Shao
Journal:  Ann Transl Med       Date:  2022-06

5.  Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Authors:  Gladys Morrison; Xiaoyong Fu; Martin Shea; Sarmistha Nanda; Mario Giuliano; Tao Wang; Teresa Klinowska; C Kent Osborne; Mothaffar F Rimawi; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2014-02-20       Impact factor: 4.872

6.  Clinicopathological significance of forkhead box protein A1 in breast cancer: A meta-analysis.

Authors:  Keli He; Hui Zeng; Xianqun Xu; Anling Li; Qing Cai; Xinghua Long
Journal:  Exp Ther Med       Date:  2016-04-06       Impact factor: 2.447

7.  Combining biomarkers to optimize patient treatment recommendations.

Authors:  Chaeryon Kang; Holly Janes; Ying Huang
Journal:  Biometrics       Date:  2014-05-30       Impact factor: 2.571

8.  Computational investigations of the binding mechanism of novel benzophenone imine inhibitors for the treatment of breast cancer.

Authors:  Amneh Shtaiwi; Rohana Adnan; Melati Khairuddean; Shafi Ullah Khan
Journal:  RSC Adv       Date:  2019-11-01       Impact factor: 4.036

9.  Prediction of breast cancer survival using clinical and genetic markers by tumor subtypes.

Authors:  Nan Song; Ji-Yeob Choi; Hyuna Sung; Sujee Jeon; Seokang Chung; Sue K Park; Wonshik Han; Jong Won Lee; Mi Kyung Kim; Ji-Young Lee; Keun-Young Yoo; Bok-Ghee Han; Sei-Hyun Ahn; Dong-Young Noh; Daehee Kang
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 10.  Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug-Design and Mechanism of Action.

Authors:  Adam J Buric; Jonathan Dickerhoff; Danzhou Yang
Journal:  Molecules       Date:  2021-07-07       Impact factor: 4.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.